Compare · NTRA vs OSCR
NTRA vs OSCR
Side-by-side comparison of Natera Inc. (NTRA) and Oscar Health Inc. (OSCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and OSCR operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $32.43B, about 3.8x OSCR ($8.52B).
- Over the past year, NTRA is up 32.6% and OSCR is up 50.3% - OSCR leads by 17.7 points.
- NTRA has been more active in the news (22 items in the past 4 weeks vs 16 for OSCR).
- Both have 25 recent analyst ratings on file.
- Company
- Natera Inc.
- Oscar Health Inc.
- Price
- $226.52+2.86%
- $28.27-1.00%
- Market cap
- $32.43B
- $8.52B
- 1M return
- +17.63%
- +11.69%
- 1Y return
- +32.57%
- +50.25%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- 2021
- News (4w)
- 22
- 16
- Recent ratings
- 25
- 25
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Oscar Health Inc.
Oscar Health, Inc. provides health insurance products and services in the United States. The company offers Individual & Family, Small Group, and Medicare Advantage plans, as well as +Oscar, a full stack technology platform. It also provides reinsurance products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was founded in 2012 and is headquartered in New York, New York.
Latest NTRA
- Director Chapman Rowan E sold $642,536 worth of shares (2,964 units at $216.78) as part of a pre-agreed trading plan, decreasing direct ownership by 49% to 3,124 units (SEC Form 4)
- CO-FOUNDER Sheena Jonathan sold $665,087 worth of shares (3,150 units at $211.14) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 249,352 units (SEC Form 4)
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $21,447,308 worth of shares (100,000 units at $214.47) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 2,277,843 units (SEC Form 4)
- Amendment: Natera Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Natera Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- RBC Capital Mkts resumed coverage on Natera with a new price target
- Director Marcus Gail Boxer sold $2,389,328 worth of shares (11,000 units at $217.21) and exercised 11,000 shares at a strike of $22.83 (SEC Form 4)
- SEC Form 3 filed by new insider Lynch Thomas J. Jr.
- CEO AND PRESIDENT Chapman Steven Leonard sold $9,089,776 worth of shares (41,124 units at $221.03) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 108,743 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest OSCR
- Oscar Health upgraded by Barclays with a new price target
- Oscar Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Lang Laura W was granted 8,475 shares, increasing direct ownership by 11% to 82,840 units (SEC Form 4)
- Director Plouffe David was granted 8,475 shares, increasing direct ownership by 7% to 137,121 units (SEC Form 4)
- Director Sankaran Sid was granted 8,475 shares, increasing direct ownership by 60% to 22,609 units (SEC Form 4)
- Director Gassen William was granted 8,475 shares, increasing direct ownership by 11% to 82,840 units (SEC Form 4)
- Director Wittman Vanessa Ames was granted 8,475 shares, increasing direct ownership by 7% to 137,121 units (SEC Form 4)
- Oscar Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Chief Accounting Officer Baltrus Victoria sold $33,417 worth of shares (1,523 units at $21.94) as part of a pre-agreed trading plan, decreasing direct ownership by 0.70% to 214,589 units (SEC Form 4) to satisfy tax liability
- Director Schlosser Mario sold $748,633 worth of shares (34,120 units at $21.94) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 480,866 units (SEC Form 4) to cover withholding tax